EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pre-clinical validation of AAV gene therapy for KCNV2 retinopathy improves visual function and expression in mouse and patient models

Rabab Rashwan, Paula I Fuller-Carter, Xin Ru Lim, Alicia A Brunet, Annie L Miller, Yashvi Bhatt, Rebekah James, Denise Anderson, Valentina Voigt, Joao A Paulo, Mehdi Mirzaei, Melissa M Mangala und 5 weitere

Molecular Therapy · 2026-11 · 34 (11) · 6402-6427

DOI: 10.1016/j.ymthe.2026.09.025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2026-11. Verfasst von Rabab Rashwan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Retinal Genomics and Therapy Group, Lions Eye Institute, Perth, WA 6009, Australia; Department of Microbiology and Immunology, Faculty of Medicine, M…. Hauptthemen laut MEDLINE: Dependovirus, Genetic Therapy, Genetic Vectors, Potassium Channels, Voltage-Gated. Die Arbeit nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lions Eye Institute, National Health and Medical Research Council, Government of Western Australia Department of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Voltage-gated (Kv) potassium channels are critical for neuronal physiology, and their dysfunction can have serious implications. For example, mutations in the silent modulatory Kv8.2 subunit are known to cause irreversible inherited blindness (KCNV2 retinopathy). This is a currently incurable condition that causes lifelong visual loss, reduced visual acuity, photophobia, night blindness, and abnormal color vision, alongside a distinctive supernormal electrophysiological (electroretinography [ERG]) retinal response to light. In this study, we demonstrate that adeno-associated virus (AAV)-mediated gene replacement therapy delivering a codon-optimized human KCNV2 gene subretinally into Kv8.2 knockout mice significantly restores retinal function. Treated mice exhibited improved ERG responses and correct expression of KCNV2 and its encoded Kv8.2 protein in photoreceptors. Recovery of visually guided scotopic and photopic optomotor reflex responses to wild-type levels was achieved even at lower vector doses, highlighting dose-dependent efficacy. Furthermore, treatment of human retinal organoids derived from a KCNV2 patient-derived induced pluripotent stem cell (iPSC) line resulted in substantial Kv8.2 protein rescue. This work provides the preclinical proof of concept for the safety and therapeutic potential of gene therapy for KCNV2 retinopathy, laying a strong foundation for future clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DependovirusGenetic TherapyGenetic VectorsPotassium Channels, Voltage-GatedRetinal DiseasesAnimalsHumansMiceDisease Models, AnimalElectroretinographyMice, KnockoutRetinaGene Therapy AgentsGene ExpressionVision, Ocular

Stichwörter der Autor:innen

AAVKCNV2 retinopathyelectroretinographygene therapyinherited retinal diseasesphotoreceptorsretinal degenerationretinal organoidsvision lossvoltage-gated potassium channels

Substanzen

Potassium Channels, Voltage-GatedKCNV2 protein, human

Autor:innen und Institutionen

  • Retinal Genomics and Therapy Group, Lions Eye Institute, Perth, WA 6009, Australia; Department of Microbiology and Immunology, Faculty of Medicine, Minia University, Minia 61519, Egypt.
  • Retinal Genomics and Therapy Group, Lions Eye Institute, Perth, WA 6009, Australia.
  • Centre for Ophthalmology and Visual Science, The University of Western Australia, Perth, WA 6009, Australia.
  • Retinal Genomics and Therapy Group, Lions Eye Institute, Perth, WA 6009, Australia; Centre for Ophthalmology and Visual Science, The University of Western Australia, Perth, WA 6009, Australia.
  • INSiGENe Pty Ltd, Perth, WA 6163, Australia.
  • Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.

Förderung

  • Lions Eye Institute
  • National Health and Medical Research Council
  • Government of Western Australia Department of Health
  • Department of Health, Government of Western Australia

Zitieren

APA

Rashwan, R., Fuller-Carter, P. I., Lim, X. R., Brunet, A. A., Miller, A. L., Bhatt, Y., James, R., Anderson, D., Voigt, V., Paulo, J. A., Mirzaei, M., Mangala, M. M., Wong, E. O., Jamieson, R. V., Gonzalez-Cordero, A., Hunt, D. M., & Carvalho, L. S. (2026). Pre-clinical validation of AAV gene therapy for KCNV2 retinopathy improves visual function and expression in mouse and patient models. Molecular Therapy, 34(11), 6402-6427. https://doi.org/10.1016/j.ymthe.2026.09.025

Vancouver

Rashwan R, Fuller-Carter PI, Lim XR, Brunet AA, Miller AL, Bhatt Y, et al. Pre-clinical validation of AAV gene therapy for KCNV2 retinopathy improves visual function and expression in mouse and patient models. Molecular Therapy. 2026;34(11):6402-6427. doi:10.1016/j.ymthe.2026.09.025

BibTeX
@article{Rashwan2026,
  author = {Rashwan, Rabab and Fuller-Carter, Paula I and Lim, Xin Ru and Brunet, Alicia A and Miller, Annie L and Bhatt, Yashvi and James, Rebekah and Anderson, Denise and Voigt, Valentina and Paulo, Joao A and Mirzaei, Mehdi and Mangala, Melissa M and Wong, Emilie O and Jamieson, Robyn V and Gonzalez-Cordero, Anai and Hunt, David M and Carvalho, Livia S},
  title = {Pre-clinical validation of AAV gene therapy for KCNV2 retinopathy improves visual function and expression in mouse and patient models},
  journal = {Molecular Therapy},
  year = {2026},
  volume = {34},
  number = {11},
  pages = {6402--6427},
  doi = {10.1016/j.ymthe.2026.09.025}
}
Kostenlos starten →